Search Results for keywords:"intermediates for sale"

Janssen Pharmaceuticals, Inc. has applied to the Drug Enforcement Administration to be registered as a bulk manufacturer of certain controlled substances. The DEA has issued a notice inviting public comments or objections to this application and requests for a hearing on the matter, which must be submitted by April 21, 2025. Comments can be made electronically through the Federal eRulemaking Portal. Janssen plans to manufacture these substances for use as intermediates in sales to customers, and no other activities are allowed under this registration.